Co vypovídá registr TULUNG o trendech ve využití nákladné léčby u NSCLC?

• Title in English: What does the TULUNG register say on the trends in costly pulmonary onological treatment of advanced non-small cell cancer?
• Authors: SKŘIČKOVÁ Jana; BORTLÍČEK Zbyněk; HEJDUK Karel; PEŠEK M.; ZATLOUKAL P.; KOLEK V.; SALAJKA F.; KOUBKOVÁ L.; TOMÍŠKOVÁ Marcela; ŠATÁNKOVÁ M.; POVOLNÁ Z.; GRYGÁRKOVÁ Y.; HAVEL L.; HRNČIARIK M.; ZEMANOVÁ M.; SIXTOVÁ D.; ROUBEC J.; ČOUPKOVÁ H.; KOŠATOVÁ K.; ČERNOVSKÁ M.; MAREL M.; VAŠÁKOVÁ M.
• Year of publication: 2013
• Type: Conference abstract
• MU Faculty or unit: Faculty of Medicine
• Description: The authors discuss how current rules for administering pemetrexed, erlotinib, gefinitib, or bevacizumab influence their use in the treatment of advanced non-small cell cancer in the Czech Republic.